Eli Lilly and Company (FRA:LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 610.00B |
| Revenue (ttm) | 45.34B |
| Net Income (ttm) | 10.28B |
| Shares Out | n/a |
| EPS (ttm) | 11.37 |
| PE Ratio | 59.36 |
| Forward PE | 30.17 |
| Dividend | 5.05 (0.78%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 57 |
| Average Volume | 676 |
| Open | 684.80 |
| Previous Close | 684.70 |
| Day's Range | 681.20 - 684.80 |
| 52-Week Range | 616.90 - 888.80 |
| Beta | n/a |
| RSI | 44.19 |
| Earnings Date | May 1, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
4 stocks to watch on Monday: AAPL, NRG, FOX/FOXA and LLY
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly's Zepbound outshines Wegovy in a Phase 3b trial, delivering superior weight loss results.
Here’s how much extra weight is lost with Zepbound over Wegovy
A study of two blockbuster weight-loss drugs came out in favor of Eli Lilly over its rival Novo Nordisk.
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Eli Lilly and Company’s (NYSE: LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE: NVO) Wegovy in a 72-week head-to-head trial. What Happened: Participants tre...
Eli Lilly's (LLY) Zepbound Outperforms Novo Nordisk's Wegovy in Weight Loss Study
Eli Lilly's (LLY) Zepbound Outperforms Novo Nordisk's Wegovy in Weight Loss Study
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circ...
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly in...
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, wit...
Dividend Roundup: Eli Lilly, Pepsico, Ford, Delta Air Lines, and more
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...
Why Eli Lilly is falling plus, what new Costco sales say about the consumer
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Top Stock Movers Now: AB InBev, Molson Coors, Eli Lilly, and More
U.S. equities gained at midday when the U.S. and U.K. struck a new trade deal.
Tesla and Google surge as healthcare sector falters in mixed market
Today's Market Overview The US stock market presents a mixed picture today, with notable performances in the consumer cyclical and communication services sectors. Giants like Tesla and Google are emer...
Lilly announces transitions in executive leadership
INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-t...
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed during a market dip. Here's the latest transactions made by the c...
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly's blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, ...
Healthy Returns: Novo Nordisks Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.